Psychiatry

A new study found antidepressant use drops by nearly 50% during pregnancy, but without increased psychotherapy, raising concerns about untreated depression risks.

Drs. Levine and Sisti discuss the ethical challenges of GLP-1 drug allocation, exploring fairness, disparities, and policy solutions for obesity and diabetes treatment.

This Month in Review highlights the top psychiatry news in January.

The trend warrants attention, given treatment difficulties and the association with other substance use issues, says lead author of Rutgers Health study.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

GH Research's phase 2b trial found GH001, an inhalable 5-MeO-DMT treatment, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

A new study found stimulant use in children dropped 19% early in the pandemic but rebounded, with the 2022 Adderall shortage prompting shifts to alternatives.

The FDA approved updated labeling for viloxazine ER capsules as an ADHD treatment, adding lactation data and details on serotonin 5-HT2C receptor activity.

Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.

A study found depressive symptoms in older individuals with normal cognition were linked to amyloid pathology in APOE ε4 noncarriers but not carriers.

A new study showed sedative, hypnotic, and anxiolytic use disorder diagnoses rose 3- to 5-fold from 2001–2019 among adolescents and young adults.

A new study identified psychiatric, neurological, and somatic comorbidities of intermittent explosive disorder.

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.

Mindfulness eased opioid cravings in OUD patients on buprenorphine but showed no added benefit over recovery support for abstinence, substance use, or anxiety.

The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.

A new study shows that employee stress improves when using a mindfulness meditation app for under or above 5 minutes (the more effective option).

Despite the surge in telemental health use in patients with schizophrenia, fewer people in racial or ethnic minority groups had a telemental health visit compared to White people.

Boehringer Ingelheim’s phase 3 trial of iclepertin for cognitive impairment in schizophrenia failed to meet primary and secondary endpoints, showing no significant effects.

A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.

A study showed age and sex perform better at identifying the risk for opioid use disorder than candidate genetic variants.

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.

A new study found that depression prevalence among older adults was greater for those who were 65 – 69 years old.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

New research reveals that frequent social media use, especially active use of platforms such as TikTok and Facebook, is linked to greater irritability levels.